Sugi Predict

Sugi Predict / Compounds / SCHEMBL525787

SCHEMBL525787

SCHEMBL525787

NC(=S)NCCc1ccccc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 5/20 0.70
▸ RAB9A P51151 5/20 0.70
▸ SMN1; SMN2 Q16637 3/20 0.70
▸ IDO1 P14902 3/20 0.67
▸ LMNA P02545 3/20 0.67
▸ GAA P10253 1/20 0.67
▸ TAAR1 Q96RJ0 1/20 0.67
▸ CA12 O43570 2/20 0.63
▸ CA2 P00918 2/20 0.63
▸ CA9 Q16790 2/20 0.63
▸ CA1 P00915 1/20 0.63
▸ MAOA P21397 2/20 0.59
▸ MAOB P27338 2/20 0.59
▸ KMT2A Q03164 3/20 0.54
▸ ALDH1A1 P00352 3/20 0.54
▸ MEN1 O00255 2/20 0.54
▸ MAPT P10636 2/20 0.54
▸ ALOX12 P18054 2/20 0.54
▸ HTT P42858 2/20 0.54
▸ MGLL Q99685 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyridine SCHEMBL6763848 0.89 RAB9A (0.58) NPC1RAB9ASMN1; SMN2IDO1LMNA
SCHEMBL3911693 0.88 KMT2A (0.62) NPC1RAB9ASMN1; SMN2IDO1LMNA
SCHEMBL5533037 0.86 KMT2A (0.56) NPC1RAB9ASMN1; SMN2LMNAKMT2A
SCHEMBL9176170 0.86 NPC1 (0.68) NPC1RAB9ASMN1; SMN2IDO1LMNA
SCHEMBL4020005 0.86 NPC1 (0.68) NPC1RAB9ASMN1; SMN2IDO1LMNA
SCHEMBL17956753 0.85 TRPV1 (0.58) NPC1RAB9ASMN1; SMN2LMNAKMT2A
SCHEMBL3421288 0.84 IDO1 (0.58) NPC1RAB9ASMN1; SMN2IDO1LMNA
SCHEMBL11746910 0.84 NPC1 (0.66) NPC1RAB9ASMN1; SMN2IDO1LMNA
Methane SCHEMBL8530831 0.84 NPC1 (0.66) NPC1RAB9ASMN1; SMN2IDO1LMNA
Methane SCHEMBL2796518 0.84 NPC1 (0.66) NPC1RAB9ASMN1; SMN2IDO1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105772088-B (S) Mn-Anderson types heteropolyacid catalyst thiourea modified -1- (1- phenethyls), preparation method and applications 上海应用技术学院 2018-07-10 — — CN claimed
CN-105854940-B (R) Cr-Anderson types heteropolyacid catalyst thiourea modified -1- (1- phenethyls), preparation method and applications 上海应用技术学院 2018-05-15 — — CN claimed
CN-105772101-B The Mn Anderson types heteropolyacid catalyst of 1 Phenethylthiourea modification, preparation method and applications 上海应用技术学院 2018-03-30 — — CN claimed
CN-105833911-B The Cr Anderson types heteropolyacid catalyst of 1 Phenethylthiourea modification, preparation method and applications 上海应用技术学院 2018-03-09 — — CN claimed
CN-106622371-A (R)-1-(1-phenethyl)thiourea modified Al-Anderson type heteropolyacid catalyst and preparation method and application thereof 上海应用技术大学 2017-05-10 — — CN claimed
CN-106513044-A (R)-1-(1-phenethyl)thiourea unilaterally modified Fe-Anderson heteropolyacid catalyst as well as preparation method and application thereof 上海应用技术大学 2017-03-22 — — CN claimed
CN-106475139-A (S) the unilateral Fe Anderson type heteropolyacid catalyst modified of 1 (1 phenethyl) thiourea, preparation method and applications 上海应用技术大学 2017-03-08 — — CN claimed
CN-106475142-A The unilateral Fe Anderson type heteropolyacid catalyst modified of 1 Phenethylthiourea, preparation method and applications 上海应用技术大学 2017-03-08 — — CN claimed
CN-106475138-A (S)‑1‑（1 phenethyl）Thiourea modified Al Anderson type heteropolyacid catalyst, preparation method and applications 上海应用技术大学 2017-03-08 — — CN claimed
CN-105833911-A 1-Phenethylthiourea modified Cr-Anderson heteropolyacid catalyst, and preparation method and application thereof 上海应用技术学院 2016-08-10 — — CN claimed
CN-105772101-A 1-phenethyl thiourea modified Mn-Anderson type heteropolyacid catalyst and preparation method and application thereof 上海应用技术学院 2016-07-20 — — CN claimed
EP-1611109-A4 NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO LTD (JP) 2009-06-24 — — EP claimed
JP-2006522109-A — — 2006-09-28 — — JP claimed
EP-1611109-A1 NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO., LTD (JP) 2006-01-04 — — EP claimed
WO-2004087680-A1 NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO., LTD. (JP) 2004-10-14 — — WO claimed
US-4177072-A HYDROPHILIC AND OLEOPHILIC AREAS FUJI PHOTO FILM CO., LTD. (JP) 1979-12-04 — — US claimed
US-11814366-B2 Antiviral compounds and use thereof UNIVERSITA DEGLI STUDI DI SIENA (IT) 2023-11-14 — — US disclosed
EP-3765454-B1 ANTIVIRAL COMPOUNDS AND USE THEREOF UNIV DEGLI STUDI DI SIENA (IT) 2023-11-08 — — EP disclosed
US-4085119-A ANTIBACTERIAL PFIZER INC. (US) 1978-04-18 — — US disclosed
US-4008228-A Process for preparing 3-methyl-3-cephem antibiotics ELI LILLY AND COMPANY (US) 1977-02-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11814366-B2 Antiviral compounds and use thereof MAVS, EIF2AK2, SARS1 NPC1 187/4885RAB9A 1894/4885SMN1; SMN2 2276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.